Literature DB >> 12059123

Cancer antigen 125 in patients with chronic liver disease.

Harshad Devarbhavi1, Dorothy Kaese, Amy W Williams, Jorge Rakela, George G Klee, Patrick S Kamath.   

Abstract

OBJECTIVES: To determine the association between elevated levels of serum cancer antigen (CA) 125 and liver disease and to explore the possibility that CA 125 is produced by the peritoneum as a nonspecific response to the presence of fluid in the peritoneal cavity. PATIENTS AND METHODS: Between June and October 1992, CA 125 levels were measured in serum stored from 50 consecutive patients with cirrhotic ascites, 20 patients with cirrhosis but without ascites, and 12 patients with acute viral hepatitis without ascites. Serum CA 125 was also measured in 4 patients with chronic renal failure before and after initiation of continuous ambulatory peritoneal dialysis.
RESULTS: Levels of CA 125 were elevated in patients with all forms of liver disease, especially in those with cirrhotic ascites irrespective of the etiology of cirrhosis or the presence of spontaneous bacterial peritonitis or hepatocellular carcinoma. Levels of CA 125 did not change significantly 1 month after initiation of continuous ambulatory peritoneal dialysis.
CONCLUSION: Cancer antigen 125 is elevated in patients with acute and chronic liver disease, especially in those with cirrhotic ascites. This elevation in CA 125 is not because of a nonspecific response of the peritoneum to fluid in the peritoneal cavity. Awareness of the association of elevated CA 125 in patients with cirrhotic ascites can prevent unnecessary surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12059123     DOI: 10.4065/77.6.538

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Recent developments in the first detection of hepatocellular carcinoma.

Authors:  Joseph B Lopez
Journal:  Clin Biochem Rev       Date:  2005-08

2.  Differentiation of tuberculous peritonitis from peritonitis carcinomatosa without surgical intervention.

Authors:  Muhsin Kaya; Mehmet A Kaplan; Abdurrahman Isikdogan; Yusuf Celik
Journal:  Saudi J Gastroenterol       Date:  2011 Sep-Oct       Impact factor: 2.485

Review 3.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

4.  NonHodgkin's Lymphoma with Peritoneal Localization.

Authors:  E Curakova; M Genadieva-Dimitrova; J Misevski; V Caloska-Ivanova; V Andreevski; B Todorovska; U Isahi; M Trajkovska; P Misevska; N Joksimovic; S Genadieva-Stavric; S Antovic; N Jankulovski
Journal:  Case Rep Gastrointest Med       Date:  2014-03-09

5.  Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.

Authors:  Mehdi Assmar; Sara Yeganeh; Fariborz Mansourghanaei; Nour Amirmozafari
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

6.  Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma.

Authors:  Chuang Qin; Yan Gao; Jiangfa Li; Chao Huang; Songqing He
Journal:  Oncol Lett       Date:  2021-04-22       Impact factor: 2.967

7.  New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer.

Authors:  K R Hossain; J D Escobar Bermeo; K Warton; S M Valenzuela
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

8.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer.

Authors:  N Ahmed; G Barker; K T Oliva; P Hoffmann; C Riley; S Reeve; A I Smith; B E Kemp; M A Quinn; G E Rice
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

9.  The Significance of Serum CA-125 Elevation in Chinese Patients with Primary Budd-Chiari Syndrome: A Multicenter Study.

Authors:  De-Lei Cheng; Hao Xu; Wei-Fu Lv; Rong Hua; Hongtao Du; Qing-Qiao Zhang
Journal:  Gastroenterol Res Pract       Date:  2015-09-15       Impact factor: 2.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.